Preliminary analysis of combined romosozumab and denosumab versus teriparatide and denosumab on bone mineral density.

Osteoporos Sarcopenia · 2025 · PMC12766607 · PMID 41498097

Europe PMC DOI

hedged sentence

0.1780

closest p · 3.6× alpha

0.1780

boldest claim

The sentences

showed a trendP = 0.178not close (p > 0.1)

did not reach statistical significanceno p-value reported

Group B showed a trend towards improvement at 3 months (+1.67 ± 1.16%, P = 0.178) and at 6 months (+2.07 ± 1.21%, P = 0.115), although these changes did not reach statistical significance.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.